As noted in several of the comments, and as described in the study by Jackson et al., more and more investigators and public health agencies are relying on the test-negative study design to monitor influenza vaccine effectiveness at the population level.
What advantages does this approach have over traditional case-control or cohort studies? What are its key limitations?
Is this approach to studying vaccine effectiveness valid for the live attenuated influenza vaccine (LAIV), which relies on local mucosal replication, and thus could impact one's susceptibility to other respiratory pathogens?
Easy one-click social registrationIs this safe?
We only receive the minimum information necessary to verify your account. We never get access to your friends/contacts or your profile, and we never post on your behalf. Your social account is used for logging in only.ORRegister via email
Send me updates on this Contest
In order to ensure a fair voting process and to make sure that no one votes more than once, we ask that you register either with a social networking account (easiest, only requires one click) or by registering with your email address (this will require you to click on a verification email that we will send you).
You only need to register once.